Literature DB >> 24355812

α1-antitrypsin deficiency and the hepatocytes - an elegans solution to drug discovery.

Linda P O'Reilly1, David H Perlmutter1, Gary A Silverman1, Stephen C Pak2.   

Abstract

Hepatocytes are metabolically active cells of the liver that play an important role in the biosynthesis of proteins including α1-antitrypsin. Mutations in the α1-antitrypsin gene can lead to protein misfolding, polymerization/aggregation and retention of protein within the endoplasmic reticulum of hepatocytes. The intracellular accumulation of α1-antitrypsin aggregates can lead to liver disease and increased likelihood of developing hepatocellular carcinomas. Of note, only ~10% of individuals with α1-antitrypsin-deficiency develop severe liver disease suggesting that there are other genetic and/or environmental factors that determine disease outcome. The nematode, Caenorhabditis elegans, is a powerful genetic model organism to study molecular aspects of human disease. In this review, we discuss the functional similarities between the intestinal cells of C. elegans and human hepatocytes and how a C. elegans model of α1-antitrypsin-deficiency can be used as a tool for identifying genetic modifiers and small molecule drugs.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C. elegans; Hepatocyte; Liver disease; Protein aggregation; α1-Antitrypsin deficiency

Mesh:

Year:  2013        PMID: 24355812      PMCID: PMC3970812          DOI: 10.1016/j.biocel.2013.12.006

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  30 in total

Review 1.  Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury.

Authors:  David H Perlmutter
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  The natural history of liver disease in alpha 1-antitrypsin deficient children.

Authors:  T Sveger
Journal:  Acta Paediatr Scand       Date:  1988-11

3.  Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice.

Authors:  J A Carlson; B B Rogers; R N Sifers; M J Finegold; S M Clift; F J DeMayo; D W Bullock; S L Woo
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.

Authors:  T Sveger
Journal:  N Engl J Med       Date:  1976-06-10       Impact factor: 91.245

Review 5.  Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys.

Authors:  Frederick J de Serres
Journal:  Chest       Date:  2002-11       Impact factor: 9.410

6.  Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.

Authors:  J A Burrows; L K Willis; D H Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency.

Authors:  David A Rudnick; Yunjun Liao; Jae-Koo An; Louis J Muglia; David H Perlmutter; Jeffrey H Teckman
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

8.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson; J Carlson; R Velez
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

9.  Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease.

Authors:  Helen Parfrey; Ravi Mahadeva; Neil A Ravenhill; Aiwu Zhou; Timothy R Dafforn; Richard C Foreman; David A Lomas
Journal:  J Biol Chem       Date:  2003-06-13       Impact factor: 5.157

10.  Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency.

Authors:  Nunzia Pastore; Keith Blomenkamp; Fabio Annunziata; Pasquale Piccolo; Pratibha Mithbaokar; Rosa Maria Sepe; Francesco Vetrini; Donna Palmer; Philip Ng; Elena Polishchuk; Simona Iacobacci; Roman Polishchuk; Jeffrey Teckman; Andrea Ballabio; Nicola Brunetti-Pierri
Journal:  EMBO Mol Med       Date:  2013-02-04       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.